EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

The 2025 EULAR rheumatoid arthritis recommendations abandon prognostic-factor stratification after methotrexate failure and endorse less frequent laboratory monitoring after early tolerance, both directly relevant to ambulatory pharmacists managing DMARD regimens and adherence.

methotrexateglucocorticoidsbDMARDsJAK inhibitorstsDMARDscsDMARDsleflunomidesulfasalazinerheumatoid arthritisEULARtreat-to-targetbiosimilarsguideline updatedeprescribingmedication monitoring Rheumatology / Immunology

Background Information

New EULAR guidelines redefine RA management with DMARDs.

Updated EULAR recommendations aid in optimizing rheumatoid arthritis management through informed use of DMARDs based on recent evidence. The recommendations emphasize starting with methotrexate and glucocorticoids, adding biological DMARDs if needed, and considering JAK inhibitors carefully. These guidelines integrate safety considerations like cardiovascular risks, providing a structured approach to therapy escalation and tapering in rheumatoid arthritis. Updated EULAR guidelines streamline RA treatment with evidence-backed DMARD usage.

Authors: Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, Dörner T, Hyrich KL, Mateus E, Pope JE, Primdahl J, de Souza S, Stamm T, Takeuchi T, van der Heijde D, Verschueren P, Winthrop KL, Alvaro-Gracia JM, Askling J, Bathon J, Buch MH, Burmester GR, Codreanu C, Conaghan PG, Cutolo M, Fautrel B, Fonseca J, Gossec L, Haavardsholm E, Hetland ML, Iagnocco A, Juge PA, Li Z, Moe RH, Nash P, Poór G, Rubbert-Roth A, Sobrin RDS, Schulze-Koops H, Shumnalieva R, Senolt L, Silva-Fernandez L, Strangfeld A, Taylor P, Turesson C, van Duuren E, de Wit M, Xavier R, Kerschbaumer A, Landewé RBM

Citation: Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Annals of the rheumatic diseases. 2026;85(6):991-1009. doi:10.1016/j.ard.2026.01.023

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Confirmatory Impact 4/5

A rigorously developed, high-consensus (all items mean level of agreement above 9/10) guideline that reinforces the established methotrexate-plus-glucocorticoid-first treat-to-target paradigm while making one meaningful practice refinement, eliminating csDMARD stratification after MTX failure, without introducing new drug classes.

Evidence Grade: Moderate

The core algorithm rests on high-quality randomized evidence and strong expert consensus, but several updated elements (JAKi cycling, reduced monitoring intervals) derive from observational data or lack of eligible controlled studies, introducing risk of bias and indirectness that lower overall certainty.

⚡ Bottom Line

After methotrexate plus short-term glucocorticoids fail, escalate directly to a biologic (or a JAK inhibitor after cardiovascular/malignancy risk assessment) rather than cycling to a second conventional DMARD.

Editor's Note

This submission's stated abstract (medication management during care transitions) does not match the attached full text, which is the EULAR 2025 RA management guideline; this analysis is based on the actual full-text content. The corrected PubMed record (PMID 41826212) has been applied per reviewer feedback. The reduced-monitoring guidance is characterized by the task force as supported by observational data with no eligible articles in a dedicated SLR, verify before applying to institutional monitoring protocols. Extensive author industry disclosures should be noted by editors.